Work

Clinical Outcomes with Pembrolizumab and Nivolumab in Resected Advanced Melanoma: Real-World Evidence

Year: 2025

Type: article

Abstract: Background: KEYNOTE 054 and CheckMate 238 are pivotal RCTs (randomized controlled trials) evaluating the efficacy of Pembrolizumab and Nivolumab in improving recurrence-free survival (RFS) in resected stage III/IV melanoma. The corresponding overall survival (OS) data for both studies are not yet mature. This study aims to evaluate the real-world clinical outcomes of Pembrolizumab and Nivolumab in patients with resected advanced cutaneous melanoma, comparing these results with those from clinical trials using data from the Baden-Württemberg State Cancer Registry (BWCR).

Source: EJC Skin Cancer

DOI: 10.1016/j.ejcskn.2025.100528

Authors: I. Surovtsova, T. Vogel, C. Bauer-Auch, P. Morakis

Institution: Krebsregister Baden-Württemberg

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,340